Anupam Rasayan India Management Guidance Tracker
7 forward-looking guidance items tracked across 2 quarters.
Other
Management targets reducing working capital days from ~250 to below 200 by FY27, with near-term goal of ~220 days.
Q4 FY26Effective tax rate on standalone basis to be ~25% going forwardActiveManagement guided for a lower tax rate of around 25% on standalone operations.
Growth
The acquisition of J-Hawk Pine Chemicals is expected to be earnings accretive immediately upon consolidation, expected in Q4 FY26.
Q3 FY26Growth momentum to continue into next fiscal yearTrackedManagement remains optimistic about growth momentum continuing into FY27, supported by pipeline visibility and deeper customer relationships.
Q4 FY26Standalone revenue growth of 20-30% CAGR over 3-5 yearsTrackedManagement expects standalone business to grow at 20-30% annually, driven by order book conversion and new molecule commercialization.
Q4 FY26Bliss GVS Pharma capacity utilization to reach 60-70% in near to medium termTrackedManagement plans to increase Bliss's capacity utilization from 30% to 60-70%, leveraging Anupam's customer relationships and expertise.